BSECompany Update3 Nov 2026 · 3 Nov 2026, 07:44 pm

Submission of Investor Presentation for the Earnings Call scheduled on Wednesday, November 04, 2026.

Evonile Pharma Ltd · 500672

✦ AI SummaryResults

Evonile Pharma Ltd submitted an investor presentation for an earnings call scheduled on November 04, 2026, under Regulation 30 of the SEBI Listing Regulations.

Analysis Scores

Earnings Impact5/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Evonile Pharma Ltd - 500672 - Announcement under Regulation 30 (LODR)-Investor Presentation

Attachments (1)

📄

3b6c14a5-4a02-43ff-ad7a-a6af35399083.pdf

pdf

Download →
View document text
Evonile Pharma Limited (formerly known as Novartis India Limited) November 03, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 500672 Subject: Submission of Presentation for the Earnings Call scheduled with Investors / Analyst s to be held on Wednesday, November 04, 2026 . Dear Sir/Madam, This is further to our intimation dated October 26, 2026, submitted pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (th e “SEBI Listing Regulations”), regarding the Earnings Call with investors and analysts o f Evonile Pharma Limited (formerly known as Novartis India Limited) (the “Company”), scheduled to be held on Wednesday, November 04, 2026 at 2:30 P.M. (IST) through virtual mode . In compliance with Regulation 30 read with Part A of Schedule III of the SEBI Listing Regulations, we hereby enclose the investor presentation to be made at the aforesaid Earnings Call and request you to take the same on record and disseminate it on your w ebsite. Pursuant to Regulation 46(2) of the SEBI Listing Regulations, the aforesaid presentation is also available on the Company's website and can be accessed at: https://evonilepharma.com/earnings -call/ We hereby confirm that the enclosed presentation does not contain any unpublished price sensitive information and that nothing contained therein shall be construed as unpublished price sensitive information within the meaning of the applicable provisions o f the SEBI Listing Regulations and other applicable laws. This disclosure is being made for your information and records. Kindly take the above on record. Thank you. For Evonile Pharma Limited (formerly known as Novartis India Limited ) Chandni Maru Company Secretary and Compliance Officer A60291 Registered Office: Inspire BKC, 7th Floor, Bandra -Kurla Complex, Bandra (East) , Mumbai - 400051, Maharashtra, India . CIN: L24200MH1947PLC006104 | T el: +91 22 50243000 Email: investor.relations@evonilepharma.com | W ebsite: www.evonilepharma.com (formerly known as Novartis India Limited) I N V E S T O R P R E S E N T A T I O N November 3, 2026 B S E S C R I P C O D E : 5 0 0 6 7 2 I M P O R T A N T N O T I C E Disclaimer This presentation has been prepared by the management of Evonile Pharma Limited (formerly know as Novartis India Limited) (the “Company” or “Evonile”) solely for the information of the recipients. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be “forward-looking statements” based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to di(cid:257)er materially from those expressed or implied by such statements, including future changes or developments in the Company’s business, its competitive environment and political, economic, legal and social conditions. Past performance is not necessarily indicative of future results. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments. This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person, and does not constitute an o(cid:257)er or invitation to purchase or subscribe for any securities. No part of it should form the basis of, or be relied upon in connection with, any investment decision or any contract or commitment to purchase or subscribe for any securities. Evonile Pharma Limited · Investor Presentation 2 Where potential peaks Evonile Pharma Limited · Investor Presentation C O M P A N Y O V E R V I E W Company snapshot Scaled, Market-leading House with a Long Legacy Brands Years since India-focused 79+ 100% founding business Years listed on the Brands with ₹30 cr+ 43 6 BSE Revenue1 Evonile Pharma Limited · Investor Presentation (1) As per IQVIA MAT Sep’26 4 C O M P A N Y O V E R V I E W Legendary Brands, Untapped Focus DECADES OF HERITAGE PRESCRIBER EQUITY INTACT UNTAPPED POTENTIAL • Decades-old portfolio; several brands • High unaided recall among HCPs • Previously taken to market via partner- set the reference standard in their led, outsourced distribution • Prescription pull sustained with minimal category recent promotion • Brands have untapped headroom • Original-molecule pedigree anchors • Awareness spans metro, Tier 1 and Tier brand identity and quality perception 2, beyond key accounts • Deep-rooted familiarity across prescribers and chemists nationwide THE ACTIVATION GAP: • No dedicated field force behind these brands today; demand runs on legacy prescriber loyalty alone • Re-establishing in-house, focused promotion is the platform's single largest value unlock Evonile Pharma Limited · Investor Presentation 5 B R A N D P O R T F O L I O Flagship brands hold leadership across priority therapies Cardiology Pain Management Gynaecology Wellness (VMN) Neuro (CNS) Transplant RPM: 11,398 Cr+ RPM: 1,696 Cr+ RPM: 155 Cr+ RPM: 2,840 Cr+ RPM: 585 Cr+ RPM: 975 Cr+ Calcium- Minipress XL® Voveran® Methergin® Tegrital® Myfortic Sandoz® Orals Orals, Injectables, Topicals Orals, Injectables Injectables Orals Orals #1 #1 #1 #1 #1 #1 CVM rank CVM rank CVM rank CVM rank CVM rank CVM rank Macalvit® Simulect Orals Injectables #1 #1 CVM rank CVM rank Evonile Pharma Limited · Investor Presentation (1) Source: IQVIA TSA MAT Sep’26; RPM: Internal Represented Market; CVM: Covered Market 6 C O M P A N Y O V E R V I E W Financial snapshot Revenue From Operation and PAT (₹ crore) Revenue CAGR FY23-26 356 354 PAT CAGR FY23-26 103 101 Net cash as of Mar’26 FY23 FY24 FY25 FY26 Revenue From Operation PAT Evonile Pharma Limited · Investor Presentation 7 B U S I N E S S P E R F O R M A N C E A transition quarter: brands back in-house, Minipress XL added, field force being built Q 2 A N D H 1 F Y 2 7 MD & CEO’s message Following the transition from Novartis AG, Evonile Pharma has made substantial progress in just a few months. We are transitioning from a single-customer-dependent business model to an independent pharmaceutical company with our own distribution, sales and marketing capabilities. This shift requires a new organizational foundation, and the key building blocks are being put in place. These capabilities will provide the foundation for establishing Evonile as one of India’s progressive and forward-looking domestic pharmaceutical companies. During the quarter, we completed two strategic transactions: the acquisition of Minipress XL and an ophthalmology in-licensing agreement. Both strengthen our portfolio and create new platforms for sustainable growth. In H2 FY27, our focus will be on completing the organizational build-out, establishing an appropriate cost structure and bringing together a strong leadership & operating team to drive Evonile’s next phase of growth. We are laying the foundations of an organization with the capabilities, ambition and strategic direction to unlock the full potential of Evonile Pharma.” Dr. Vikas Gupta Dr. Vikas Gupta Managing Director & CEO Evon [Showing first 8,000 characters — download PDF for full document]